Delcath Systems Stock News

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q1 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -16.85% and 3.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today repor

NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, ann

Recommends Special Arrangement Designation Which Increases Reimbursement Options Recommends Special Arrangement Designation Which Increases Reimbursement Options

20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold 20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q4 2020 Results - Earnings Call Transcript

The stock price of Delcath Systems, Inc. (NASDAQ: DCTH) fell by over 30% pre-market. This is why it happened.

Delcath Systems Inc (NASDAQ: DCTH) has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patient

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today rep

Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, ann

Delcath Systems develops drug/device combos to treat liver cancers. The company's stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data.

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:  DCTH   ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today